







an Open Access Journal by MDPI

# **Oncogenes in Cancer 2.0**

Guest Editor:

#### Dr. Ignacio Gil-Bazo

Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain

Deadline for manuscript submissions:

closed (30 September 2023)

### Message from the Guest Editor

Dear Colleagues,

This Special Issue is the second edition of a previous one, "Oncogenes in Cancer".

The first oncogenes were discovered more than three decades ago. Since then, remarkable development has been achieved by the scientific community unraveling the biological impact of these oncogenes in the development and progression of different neoplasms as well as their potential clinical applicability in the design of targeted therapies. All this knowledge has made it possible to conceive of the personalized treatment of cancer.

In this Special Issue entitled "Oncogenes in Cancer", we approach the role of actionable genomic somatic alterations able to drive different solid tumors, their biological context, and the different therapeutic strategies evaluated.

This Special Issue is conceived as a comprehensive review of the most frequently present oncogenes in major solid malignancies, updating the most relevant advances leading to the development and eventual approval of new targeted therapeutic compounds.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**